ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 42 | November 1, 1985

Download PDF Visit The Full Archive

Related Articles

Trading In Stock Of U.S. Bioscience Halted, Newsletter Report Cited

October 9, 1992

List Of NCI Divisions, Addresses And Telephone Numbers

October 13, 1995

FDA Vs. NCI: Nothing Has Changed; Chabner “Frustrated” By Flutamide Delay

October 21, 1988

IOM Report Recommends Solutions to Problem of Medication Errors.

July 28, 2006

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

July 26, 2013

In Brief: AACR Award Lectures, Announced; Hungerford Honored for Philadelphia Chromosome Discovery

April 20, 1990